FDA clears Siemens' syngo.via, Biograph mCT features

2017 12 15 21 19 7016 Siemens Rsna 2017 400

Siemens Healthineers has received U.S. Food and Drug Administration (FDA) clearance for the latest version of its syngo.via molecular imaging (MI) software and four new system features for its Biograph mCT line of PET/CT systems.

Syngo.via VB30 for MI calculates a patient's Deauville score, which helps oncologists with initial treatment staging and evaluation for patients with both Hodgkin's and non-Hodgkin's lymphomas, according to the vendor. In parametric PET imaging developments, the software can now simultaneously display standardized uptake value (SUV), the metabolic rate of glucose, and distribution volume images simultaneously.

The platform's new PET/CT and SPECT/CT hybrid volume-rendering technique allows for 3D visualization of the disease state in a single image, the company said. Furthermore, syngo.via VB30 for MI brings improvements for the quantitative analysis of various neurological conditions via self-created or widely used databases for various disease states, according to Siemens.

On the Biograph mCT side, the FDA has also cleared four system features: QualityGuard, which runs daily and weekly quality control procedures during off-hours; FlowMotion Multiparametric PET Suite, which creates images of metabolic rate and distribution volume in addition to SUV images; OncoFreeze, which delivers images free of respiratory motion in the same time as a standard whole-body scan; and CardioFreeze, which corrects for respiratory and cardiac motion associated with cardiac PET/CT, according to the firm.

With the exception of QualityGuard, all of these features are also available on the company's Biograph Vision PET/CT system. Siemens plans to highlight these offerings at the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting in Philadelphia.

Page 1 of 436
Next Page